style='font-family:Verdana;'>Objectives: style='font-family:;'> style='font-family:Verdana;'> We sought to study the genetic polymorphisms of ABCB1 gene in post percutan'/> Genetic Polymorphisms of ABCB1 Gene in Patients Having Resistance to Clopidogrel
首页> 外文期刊>World Journal of Cardiovascular Diseases >Genetic Polymorphisms of ABCB1 Gene in Patients Having Resistance to Clopidogrel
【24h】

Genetic Polymorphisms of ABCB1 Gene in Patients Having Resistance to Clopidogrel

机译:氯吡格雷抗性患者ABCB1基因的遗传多态性

获取原文
           

摘要

style="text-align:justify;"> style="font-family:Verdana;">Objectives: style="font-family:;"> style="font-family:Verdana;"> We sought to study the genetic polymorphisms of ABCB1 gene in post percutaneous coronary intervention (PCI) patients with clopidogrel resistance. style="font-family:Verdana;">Background: style="font-family:Verdana;"> Dual antiplatelet therapy (DAPT) is a guideline mandated therapy for patients who undergo PCI. However there exists interindividual variability in drug response to the antiplatelet agents leading to recurrent?thrombotic events. Genetic polymorphisms of ABCB1 gene are one among the causes of this interindividual variability. style="font-family:Verdana;">Methods: style="font-family:Verdana;"> It is a single center prospective trial and include style="font-family:Verdana;">s style="font-family:Verdana;">221 patients who underwent PCI and were given clopidogrel as a part of DAPT. Platelet reactivity was assessed by grading of platelet activity index (PAI) and considered as high on treatment platelet reactivity (HTPR) style="font-family:Verdana;">, style="font-family:;" "=""> style="font-family:Verdana;"> style="font-family:Verdana;">i.e. style="font-family:Verdana;">, clopidogrel resistance if PAI > 5. Genetic analysis for ABCB1 C-T polymorphism was done by polymerase chain reaction (PCR) and single strand confirmation polymorphism (SSCP) analysis. style="font-family:Verdana;">Results: style="font-family:Verdana;"> Amongst 221 patients, 37 (16.7%) patients had ABCB1 C-T polymorphisms. The mean PAI value in these patients was 5.1 ± 3.0, while it was 3.5 ± 2.5 in those patients without ABCB1 C-T polymorphisms ( style="font-family:Verdana;">p style="font-family:Verdana;"> = 0.004). Compared to patients without HTPR, the occurrence of primary endpoints w style="font-family:Verdana;">as style="font-family:;" "=""> style="font-family:Verdana;"> not significantly increased in patients with HTPR except for stent thrombosis which was significantly high in patients with HTPR. HTPR was also associated with ABCB1 C-T polymorphisms ( style="font-family:Verdana;">p style="font-family:Verdana;"> = 0.04), but these polymorphisms did not predict the clinical outcome. style="font-family:Verdana;">Conclusions: style="font-family:Verdana;"> There was significant prevalence of ABCB1 C-T polymorphisms in patients with HTPR. However it was not an independent risk factor for clopidogrel resistance and also it did not influence adverse cardiovascular outcomes.
机译:style =“text-align:证明;”> style =“font-family:verdana;”>目标: style =“font-womain :;” > <跨度样式=“font-family:verdana;”>我们试图研究氯吡格雷抗性后经皮冠状动脉介入(PCI)患者的ABCB1基因的遗传多态性。 <跨度样式=“font-family:verdana;”>背景: <跨度样式=“font-family:verdana;”>双抗血小板治疗(dapt)是对接受PCI的患者的指导意见治疗。然而,对导致复发性血栓发生的抗血小板药物的药物反应中存在与血栓形成的血栓性事件的抗血小板症的可变异性。 ABCB1基因的遗传多态性是这种接合变异性的原因之一。 <跨度样式=“font-family:verdana;”>方法: style =“font-family:verdana;”>它是一个单一的前瞻性试验包括 style =“font-family:verdana;”> s style =“font-family:verdana;”> 221名接受PCI并获得氯吡格雷的患者作为DAPT的一部分。通过血小板活性指数(PAI)的分级评估血小板反应性,并认为血小板反应性(HTPR) <跨度样式=“字体家族:verdana;”>, <跨度样式= “字体系列:;” “=”“> style =”font-family:verdana;“> style =”font-family:verdana;“> IE <跨度样式=“Font-Family:Verdana;”>,Clopidogrel电阻如果PAI> 5. ABCB1 CT多态性的遗传分析通过聚合酶链反应(PCR)和单链确认多态性(SSCP)分析进行。 style =“font-family:verdana;”>结果: <跨度样式=“font-family:verdana;”>在221名患者中,37例(16.7%)患者有ABCB1 CT多态性。这些患者的平均PAI值为5.1±3.0,而没有ABCB1 CT多态性的患者为3.5±2.5( <跨度样式=“字体家族:Verdana;”> P style =“font-family:verdana;”> = 0.004)。与没有HTPR的患者相比,主要端点的发生W styled =“font-家庭:Verdana;“>作为 style =”font-family :;“”=“> y style =”font-family:verdana;“> HTPR患者除了支架外没有显着增加血栓形成W. HTPR患者患者显着高。 HTPR还与ABCB1 CT多态性相关( style =“font-family:verdana;”> p style =“font-family:verdana;” > = 0.04),但这些多态性没有预测临床结果。 d style =“font-family:verdana;”>结论: style =“font-family:verdana;”> ABCB1 CT的普遍性显着HTPR患者的多态性。然而,它不是氯吡格雷抗性的独立危险因素,并且它也没有影响不良心血管结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号